A single infusion instead of a lifetime of pills
For generations, people born with familial hypercholesterolemia have faced a lifetime of daily medication as the price of a genetic inheritance they never chose. Now, a small but significant trial has tested whether a single infusion of CRISPR-based gene therapy — VERVE-101 — might silence the underlying cause rather than merely manage its consequences. Nine participants received the treatment in this early human study, and while the highest doses produced meaningful, lasting reductions in LDL cholesterol, two serious cardiac events remind us that rewriting the human genome in a living body is still a frontier, not yet a destination.
- A one-time gene therapy infusion is being tested as a permanent replacement for fifty years of daily cholesterol medication — a stakes-high proposition for the 1.3 million Americans with inherited high cholesterol.
- Only nine people participated, yet the trial already carries the weight of two serious cardiac events: one heart attack the day after treatment and one fatal cardiac arrest five weeks later.
- An independent safety panel concluded the heart attack may be linked to the therapy itself, injecting real uncertainty into a trial that had generated enormous scientific optimism.
- Despite the complications, the panel cleared the trial to continue — the cholesterol reductions in highest-dose patients were sustained for months, and animal data hints the effect could last a lifetime.
- Verve Therapeutics is pressing forward toward a larger phase 2 trial in 2025, but the critical question — whether editing this gene actually prevents heart attacks and strokes — remains unanswered.
A single infusion as a replacement for a lifetime of pills — that is the proposition researchers are testing in a closely watched early trial of VERVE-101, a CRISPR-based gene therapy developed by Verve Therapeutics in partnership with Eli Lilly. The nine participants all carry familial hypercholesterolemia, a genetic condition in which a defective PCSK9 gene causes the liver to overproduce an enzyme that floods the bloodstream with dangerous LDL cholesterol. For these patients, the alternative to daily medication isn't a healthier lifestyle — it's a genetic reality they were born into.
The therapy targets liver cells directly, using CRISPR to silence the PCSK9 gene at its source. Among the three participants who received the highest doses, LDL cholesterol dropped measurably within a month of their single infusion. The patient given the largest dose still showed reduced levels six months later — a result that, if it holds, could represent a fundamental shift in how inherited cardiovascular disease is treated. Animal studies suggest the effect may persist for years, possibly permanently.
But the trial also produced sobering complications. One participant suffered a heart attack the day after receiving the treatment; another died of cardiac arrest five weeks later. An independent safety panel found the heart attack may be connected to the therapy, while the fatal cardiac arrest was attributed more likely to the participant's pre-existing heart disease. The panel recommended the trial continue, but the events cast a long shadow over the early optimism.
Verve plans to enroll additional participants through early 2024 and test an alternative delivery method in a parallel study, with a larger phase 2 trial potentially launching in 2025. What the current data cannot yet answer is the question patients care about most: whether silencing this gene actually prevents heart attacks and strokes over time. The promise embedded in these early results is genuine. So is the distance still left to travel.
A single infusion. That's what researchers are testing as a replacement for a lifetime of pills. In a small but closely watched trial, scientists gave nine people with familial hypercholesterolemia—a genetic condition that drives cholesterol dangerously high—a one-time dose of VERVE-101, a gene therapy developed by Verve Therapeutics in partnership with Eli Lilly. The results presented at the American Heart Association's conference this past November showed something that hasn't been seen before in humans: the therapy appeared to work, at least in the short term, and at least in the people who received the highest doses.
Familial hypercholesterolemia isn't a lifestyle problem. It's written into the genes. People with one defective copy of the PCSK9 gene produce too much of an enzyme that regulates cholesterol, and the result is LDL cholesterol—the kind that hardens into plaque inside arteries—circulating at levels that can trigger heart attacks and strokes decades earlier than they would in the general population. Current treatment means taking statins or other drugs every single day, sometimes for fifty years or more. The appeal of VERVE-101 is straightforward: edit the gene, turn off the problem, and walk away.
The therapy uses CRISPR, the gene-editing tool that has become synonymous with the possibility of fixing disease at its source. In this case, the goal is to silence the PCSK9 gene in liver cells, the organ where the problematic enzyme is made. Three participants received the highest doses, and a month after their single infusion, their LDL cholesterol had dropped noticeably. The patient who got the largest dose still showed reduced levels six months later. Animal studies suggest the effect could last for years, possibly a lifetime, though no one yet knows for certain.
But the trial also surfaced the kind of complications that make early-stage medicine cautious. Two of the nine participants experienced serious cardiac events. One had a heart attack the day after receiving the treatment. Another suffered fatal cardiac arrest five weeks later. An independent safety panel concluded that the heart attack might be connected to the therapy, while the cardiac arrest was more likely due to the participant's existing heart disease. The panel recommended the trial continue, but the incidents underscore how little is known about what happens when you edit someone's genes in a living body.
Andrew Bellinger, the chief scientific officer at Verve, framed the findings in terms of liberation: instead of managing cholesterol with daily medication for decades, patients might receive a single treatment and be done. That vision is compelling enough that the company plans to enroll more participants through early 2024 and launch a second trial testing a different delivery method. If results hold, a larger phase 2 trial could begin in 2025. About 1.3 million Americans have the form of familial hypercholesterolemia that this therapy might eventually treat.
What remains unknown is whether VERVE-101 actually prevents heart attacks and strokes—the outcomes that matter most to patients. The current trial is small and short, designed mainly to check whether the treatment is safe enough to continue. Larger, longer studies will be needed to answer whether editing genes in the liver truly changes the course of cardiovascular disease. The promise is real. The caution is warranted. The next phase of testing will determine whether this one-time intervention can deliver on what animal models suggest is possible.
Notable Quotes
Instead of daily pills or intermittent injections over decades, this study reveals the potential for a single-course therapy that may lead to deep LDL-C lowering for decades.— Andrew Bellinger, chief scientific officer at Verve Therapeutics
The Hearth Conversation Another angle on the story
Why does this matter more than just taking a statin every day?
Because statins work for some people but not all, and they require perfect adherence for decades. If you miss doses or stop taking them, your cholesterol climbs back up. With a one-time gene edit, you're changing the underlying biology, not just managing the symptom.
But two people had serious heart problems during the trial. Doesn't that suggest the therapy itself is dangerous?
It's unclear. One heart attack might be linked to the treatment; the other cardiac arrest was probably from existing disease. With only nine people, it's hard to know what's signal and what's noise. That's why they need much larger trials.
How long would the effect actually last?
In animals, the cholesterol reduction has held for at least two and a half years, possibly longer. But we don't have human data beyond six months yet. That's the honest answer.
Who would actually get this treatment?
People with familial hypercholesterolemia—the genetic kind, not the kind you get from diet. About 1.3 million Americans have it. Many are diagnosed only after a heart attack. If this works, it could change their trajectory entirely.
What happens next?
More people get enrolled in the current trial through early 2024. A second trial starts testing a different way to deliver the therapy. If both look safe, they move to a larger phase 2 trial in 2025 that will actually measure whether people have fewer heart attacks and strokes.
So we're still years away from knowing if this actually works?
Yes. The promise is real, but the evidence is preliminary. That's the nature of being first.